Your browser doesn't support javascript.
loading
Statin-Associated Necrotizing Autoimmune Myositis Complicated by an Uncommon Adverse Effect to Treatment.
Fung, Brian M; Heinze, Emil R; Wong, Andrew L.
Afiliação
  • Fung BM; UCLA-Olive View Internal Medicine Residency Program, Sylmar, CA, USA.
  • Heinze ER; Division of Rheumatology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA, USA.
  • Wong AL; Division of Rheumatology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA, USA.
Case Rep Med ; 2019: 4601304, 2019.
Article em En | MEDLINE | ID: mdl-31341481
ABSTRACT
Statin-associated necrotizing autoimmune myositis (NAM) is an autoimmune condition characterized by severe acute-onset proximal muscle weakness, a very high creatinine kinase (CK) level, and prominent myofiber necrosis and minimal lymphocytic infiltration on muscle biopsy. Unlike self-limited statin myopathy, this condition usually requires aggressive immunomodulation therapy to assist recovery and prevent future disability. In this case report, we present a patient who developed progressive muscle weakness after taking atorvastatin for one year. At initial presentation, her CK level was 28,000 U/L. She was diagnosed with statin-associated NAM and started on high-dose intravenous solumedrol, mycophenolate, and intravenous immunoglobulin (IVIG) therapy. However, she subsequently developed acute bilateral vision loss and right side hemineglect; she was diagnosed with posterior reversible encephalopathy syndrome (PRES), thought to be a possible delayed adverse reaction to IVIG. IVIG was discontinued, and the patient was treated with supportive therapy. At six-month follow-up, she had significant improvement in muscle strength and vision.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article